Capital structure strengthened
Copenhagen, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Announcement no. 01-2023
Inside Information/Capital increase
The media intelligence technology company Hypefactors, providing users with a real-time overview to reputation and trust metrics for companies, brands, competitors, industries, and trends, is pleased to announce actions which are strengthening the capital structure. A small group of investors have invested DKK 1.0 million. The share price for the capital increase is DKK 3.278, which is a ten days closing price average minus a 10% discount. As the investment is structured as a capital increase, it benefits the company’s capital structure directly.
The total number of new shares to be issued is 305,064 increasing the total number of shares from 11,138,664 to 11,443,728. Furthermore, a loan facility of DKK 1 million has been established and also previously announced loan tranches of DKK 2 million from Vaekstfonden (the Danish state’s investment fund) are up for release. These financial actions will have a positive effect on both the liquidity and equity of the company.
-----
About Hypefactors A/S
Hypefactors is an integrated AI powered Earned Media tech platform to support better media intelligence, reputation and trust management. Hypefactors combine data, analytics, technology and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to a number of facts, incl. automated documentation of the monetary value and quality assessment of each third-party media mention. The platform also contains other time-saving tools such as automatically generated media reports and a mobile app giving access to real-time media mentions. The company is listed at Nasdaq Growth Market in Copenhagen, Denmark.
For more information, please contact:
Casper Janns, CEO: Tlf.: +45 20167481, e-mail: cj@hypefactors.com
Pierre André Montjovet, Chairman of the Board: Tlf: +41 (0)78 922 33 0,
e-mail: p.montjovet@heritage.ch
Hypefactors A/S
Kronprinsessegade 8B
1306 Copenhagen K
Denmark
www.hypefactors.com
Certified Adviser
Beierholm Corporate Finance P/S
Østergade 26B
1100 København K
Kim Harpøth Jespersen, Partner, M +4552150243, email: k.jespersen@dk.oaklins.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:50:33 CET | Press release
PRESS RELEASE Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software Wolters Kluwer CCH Tagetik AI-based financial planning solution empowers finance professionals to make faster and better-informed decisions. New York – Dec. 8, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that it has been recognized as a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. Earlier this month, Wolters Kluwer also received recognition as a Leader in the Gartner Magic Quadrant for Financial Close and Consolidation Software. CCH Tagetik Budgeting, Planning and Forecasting software is Wolters Kluwer’s AI-based, enterprise-wide planning solution, which helps global companies facilitate strategic, financial, and operational planning, including supply chain, workforce, and capital expenses. The solution, which supports customers across vertical industries, is particula
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment8.12.2023 17:50:00 CET | Press release
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programme Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgery) Kadcyla® (trastuzumab emtansine) compared to Herceptin® (trastuzumab): at the 7-year landmark OS rates were 89.07% and 84.37
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation8.12.2023 17:45:00 CET | Press release
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authorities Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.1 The inavolisib combination reduced the risk of disease worsening or death (progression-free survival; PFS) by 57% compared to palbociclib and fulvestrant alone (15.0 months vs 7.3 months;
Innofactor Plc: Share Repurchase 8.12.20238.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 8.12.2023Innofactor Plc: Share Repurchase 8.12.2023In the Helsinki Stock ExchangeTrade date 8.12.2023Bourse trade BuyShare IFA1VAmount 4,400SharesAverage price/ share 1.1700EURTotal cost 5,148.00EURInnofactor Plc now holds a total of 580 029 sharesincluding the shares repurchased on 8.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 2029sami.ensio@innofactor.comwww.innofactor.com Attachment Innofactor_8.12_trades
Azerion publishes bond prospectus and applies for admission to trading of its bonds on Nasdaq Stockholm8.12.2023 17:26:44 CET | Press release
Amsterdam, 8 December 2023 – Azerion Group N.V. (the “Company”) has, on 14 September 2023, following a bookbuilding process, successfully placed EUR 165 million of senior secured floating rate bonds under a framework of EUR 300 million to qualified institutional investors internationally (the "Bonds"). The Dutch Authority for the Financial Markets (Autoriteit Financiële Markten (the “AFM”)) has on 8 December 2023 approved the prospectus in relation to the admission to trading of the Bonds (the "Prospectus"). The approval of the Prospectus has been notified to the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The Prospectus will be available on the AFM’s website (https://www.afm.nl/en/sector/registers/meldingenregisters/goedgekeurde-prospectussen) and, together with a Swedish translation of the summary of the Prospectus, on the Company’s website (https://www.azerion.com/reports/). The Company will apply for listing of the Bonds on the Corporate Bond List of Nasdaq St